Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Clinical, genetic and biological characteristics of hbs_oman: a severe unrevealed form of sickle cell disease
source: The American Society of Pediatric Hematology/Oncology
year: 2016
authors: Yasser A. Wali, Shahina Daar, Maha Alwaidy, Taimoora S. Al Subhi, Aisha ElKhayat, Shoaib AlZadjali, Aisha AlHosni, Heba Omar, Halima AlBalushi, Abdulhakim Al-rawas, Mohamed Elshinawy
summary/abstract:Background: Hemoglobin SOman results from double mutations in the β globin chain; the classic βS mutation (β6 Glu→Val), and a second mutation in the same chain (β121 Glu→Lys) identical to that of HbOArab. In the literature only 6 carriers have been described. HbS-Oman carriers can have severe clinical presentation matching sickle cell disease with frequent vaso-occlusive crises, acute chest syndrome and even cerebrovascular accidents.
Objectives: Study the clinical phenotype, genotype and cell biology of both carriers of HbSOman and compound heterozygotes HbS-SOman.
Design/Method: A cross sectional study that includes all identified carriers of HbSOman and compound heterozygotes. Demographic and clinical phenotype data were collected, including family pedigrees that were tracked to the same grandmother indicating a founder effect. Hematological parameters and HPLC were performed. β-globin chain haplotypes were done using RFLP. Next generation Exom sequencing for α-globin gene non-deletional mutations, β-gene mutations and other genetic modifiers including AHSP, BCL11a, KLF1, TAL1 and GATA1 was performed. Deletional α-thalassemia mutations were identified using α-gene scan. Samples were processed for non-electrolytic hemolysis test, K+ efflux by using radioactive tracer studies.
Results: We identified 53 carriers, 27 males and 26 females and 6 HbS-SOman patients, 4 males and 2 females, age range between 2-75 years. Hemoglobin range was 7.5-14.7 g/dl (11.9+1.6), and SOman 9.5-25.3% (15.9+3.7) for carriers, while Hb ranged from 3.2-7.8 g/dl (5.2+2.4) and SOman 6-24.6% (11.6+6.6) for compound heterozygotes. Clinical severity index correlated with the SOman percent in the carriers with a cut-off value of 14% and with decreased production of α-chains due to deletional or non-deletional mutations; however, there were no such correlations in the compound heterozygotes who presented in early infancy with severe transfusion-dependence. Other genetic modifiers seem to have no effect. Activation of a deoxygenation-induced Cl–independent K+flux, i.e. Psickle-like permeability, a lack of Gardos channel activity and minimal activity of potassium chloride co-transporter was found in SOman carriers.
Conclusion: HbSOman is a severe form of SCD; carriers can be severely symptomatic and compound heterozygotes present as thalassemia major with early transfusion dependence. Alpha thalassemia mutation is the main genetic modifier in carriers. SOman cells have increased sickling and hemolytic characteristics.
organization: Sultan Qaboos University, Al-Khodh, Omanread more
Related Content
-
What is Sickle Cell Disease?Usually, red blood cells (RBCs) are shap...
-
Implementation of the NCAA sickle cell trait screening policy: A survey of athletic staff and student-athletesObjective: To describe the perspectives...
-
Dr. Freda Gives the 411 on Sickle Cell Diseasehttps://www.youtube.com/watch?v=_aMrRu7R...
-
About Pediatric Sickle Cell Diseasehttps://www.onescdvoice.com/wp-content/u...
-
How This Disease Changes the Shape of Your Cells – Amber M. Yateshttps://www.youtube.com/watch?v=hRnrIpUM...
-
Interview with Dr. Keith Wailoo on the journey of medical and social context in treating sickle cell diseaseKeith Wailoo, Professor of history and p...
-
Sickle Cell Anemia on Smear, microscopic – Hematopathologyhttps://library.med.utah.edu/WebPath/HEM...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.